Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganke Granules
- Development stage
- Unknown
- Lead developer
- Beijing Yingkerei Pharmaceutical Technology
- Administration
- Oral
01
Overview
Ganke Granules is a Traditional Chinese Medicine (TCM) formulation developed by Yingkerui (Tianjin) Innovative Pharmaceutical Research for the treatment of post-infectious cough. It is specifically indicated for patients presenting with the 'wind-heat lingering in lung' pattern, a TCM diagnostic category. The drug is currently being evaluated in Phase 2 clinical trials in China to assess its efficacy and safety compared to placebo in adults. As a botanical/herbal product, its mechanism likely involves multi-target anti-inflammatory and antitussive effects characteristic of TCM respiratory treatments.
- Other names
- 感咳颗粒
Beyond the preview
Go deeper on Ganke Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ganke Granules.